USD 11.82 billion
Hemophilia Market Size, Share, Growth Analysis, By Disease(Hemophilia A, hemophilia B, and others), By Product(Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and others), By Therapy(As Replacement Therapy, Gene Therapy, and others), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35D2191 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
90
|Figures:
76
Hemophilia Market Insights
Hemophilia Market size was valued at USD 12.6 billion in 2022 and is poised to grow from USD 13.43 billion in 2023 to USD 23.39 billion by 2031, at a CAGR of 6.6% during the forecast period (2024-2031).
The market for hemophilia treatment is being driven by significant factors such as the approval of gene therapy for hemophilia treatment and the presence of numerous other candidates in different stages of development.
Additionally, there is a growing awareness of hemophilia disorders and increasing government support initiatives aimed at early detection in neonates, which are expected to contribute to the growth of the market.
According to the data published by the World Federation of hemophilia (WFH) in October 2021, hemophilia is more prevalent in males than females due to sex linkage. The survey conducted by WFH in 2020 reported a total of 209,614 individuals globally suffering from hemophilia, with 165,379 patients having type A, 33,076 patients having type B, and 11,159 patients having an unknown type. The high prevalence of the disorder has contributed to the increasing adoption of therapies and is driving the growth of the market.
US Hemophilia Market is poised to grow at a sustainable CAGR for the next forecast year.
Market Snapshot - 2024-2031
Global Market Size
Largest Segment
Hemophilia A
Fastest Growth
Growth Rate
6.6% CAGR
Global Hemophilia Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Hemophilia Market Segmental Analysis
The market for hemophilia is divided into various segments based on disease, therapy, product, and geography. The disease types include hemophilia A, hemophilia B, and others. Therapies used for treatment are categorized as Replacement Therapy, Gene Therapy, and others. Product types consist of Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, and others. Geographically, the market is analyzed across regions such as North America, Europe, Asia-Pacific, Middle East and Africa, and South America.
Hemophilia Market Analysis By Disease
In the market for hemophilia, the largest segment is hemophilia A, which represents a significant portion of the patient population. It affects a substantial number of individuals globally and requires specialized treatment and management.
Furthermore, the fastest growing segment in the hemophilia market is Gene Therapy. The rapid growth of gene therapy in the hemophilia market can be attributed to several factors. Firstly, gene therapy offers the possibility of reducing or eliminating the need for frequent replacement therapy, which requires regular intravenous infusions of clotting factors. This can greatly improve the quality of life for patients and reduce the burden of treatment.
As a result, the gene therapy segment in the hemophilia market is experiencing significant growth rates, with a robust pipeline of candidates under development and increasing investments in research and development.
Global Hemophilia Market By Diseases
To get detailed analysis on other segments, Request For Free Sample Report
Hemophilia Market Regional Insights
North America emerges as the dominating region in the global hemophilia market . With its advanced healthcare infrastructure, high awareness about hemophilia, and substantial investments in research and development, North America commands a significant share of the market. The region is home to key players, renowned medical institutions, and a well-established patient support system, which contribute to its leadership position. Furthermore, North America benefits from a strong regulatory framework and reimbursement policies that support access to advanced hemophilia treatments. These factors collectively position North America as the dominant region in the global hemophilia market .
Meanwhile, the Asia-Pacific region is the fastest growing region in the global hemophilia market . The region's rising population, increasing healthcare expenditure, and growing awareness about hemophilia are driving market expansion at an accelerated pace. Countries like India and China, with their large patient populations and improving healthcare infrastructure, present immense growth opportunities. The presence of emerging economies, coupled with government initiatives to enhance healthcare access and affordability, further propel the market growth in the Asia-Pacific region. With a focus on improving hemophilia management, increasing patient awareness, and fostering innovation, the Asia-Pacific region is poised to witness remarkable growth in the coming years.
Global Hemophilia Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Hemophilia Market Dynamics
Hemophilia Market Drivers
Technological Advancements
- Advances in gene therapy, recombinant factor concentrates, and personalized medicine have significantly improved treatment options for hemophilia, enhancing patient outcomes and quality of life.
- Government initiatives aimed at improving healthcare infrastructure, providing financial assistance, and enhancing patient access to treatment have created a conducive environment for market growth.
- Investments in research and development by pharmaceutical companies and academic institutions have led to the development of innovative therapies, driving market growth and expanding treatment options.
Hemophilia Market Restraints
High Treatment Costs
- Hemophilia treatments, particularly novel therapies such as gene therapy, can be expensive, posing financial challenges for patients and healthcare systems. Cost constraints can limit access to advanced treatment options.
- Access to specialized hemophilia treatment centers and comprehensive care may be limited in certain developing regions, resulting in inadequate management and treatment options for patients.
Request Free Customization of this report to help us to meet your business objectives.
Hemophilia Market Competitive Landscape
The market for hemophilia is characterized by moderate competitiveness and is dominated by a few major players. These key players have engaged in various strategic alliances such as acquisitions, collaborations, and the introduction of advanced products and research studies to establish their position in the global market.
Hemophilia Market Top Player’s Company Profiles
- Bayer AG (Germany)
- BioMarin Pharmaceutical Inc. (United States)
- CSL Behring (Australia)
- Kedrion (Italy)
- Novo Nordisk (Denmark)
- Pfizer Inc. (United States)
- Roche (Chugai Pharmaceutical Co.) (Switzerland/Japan)
- Sanofi (Genzyme Corporation) (France/United States)
- Takeda Pharmaceutical (Shire Plc.) (Japan/Ireland)
- Grifols (Spain)
- Octapharma (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Biogen (United States)
- Baxalta (United States)
- LFB Group (France)
- Bioverativ Inc. (United States)
- Bio Products Laboratory Ltd. (United Kingdom)
- Kogenate (Germany)
- Sangamo Therapeutics, Inc. (United States)
- Spark Therapeutics (United States)
Hemophilia Market Recent Developments
- In March 2022, Freeline Therapeutics Holdings plc initiated its Phase 1/2 B-LIEVE dose-confirmation clinical trial for FLT180a, a potential treatment for hemophilia B.
- In February 2022, BioMarin Pharmaceutical Inc. announced positive outcomes from a two-year analysis of the Phase 3 GENEr8-1 study and provided an overall safety update on valoctocogene roxaparvovec, an investigational gene therapy designed to treat severe hemophilia A.
Hemophilia Key Market Trends
- One key market trend in the hemophilia market is the growing adoption of gene therapy. Gene therapy has shown significant promise in providing long-term solutions for hemophilia by addressing the underlying genetic cause of the disorder. This approach involves introducing functional genes into the patient's body to produce the missing clotting factors. Gene therapy for hemophilia has gained traction due to advancements in viral vector technologies and improved understanding of genetic engineering. Several clinical trials and research studies have demonstrated positive results, showcasing the potential for gene therapy to provide long-lasting benefits and reduce the burden of frequent treatments such as factor replacement therapy.
Hemophilia Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Deployment modes team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our analyses, The hemophilia market is experiencing significant growth and transformation driven by various factors. The increasing prevalence of hemophilia, coupled with advancements in treatment options and gene therapies, is fueling market expansion. The adoption of gene therapy holds immense potential in providing long-term solutions by addressing the underlying genetic cause of the disorder. Personalized medicine and precision therapies are gaining momentum, allowing for tailored treatment plans based on individual genetic profiles and disease severity. Additionally, the integration of telemedicine and digital health solutions is revolutionizing patient care and management by enabling remote consultations, monitoring, and access to educational resources. These market trends indicate a shift towards innovative and targeted approaches, which are poised to improve the quality of life for individuals living with hemophilia.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 12.6 billion |
| Market size value in 2031 | USD 23.39 billion |
| Growth Rate | 6.6% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Hemophilia Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Hemophilia Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Hemophilia Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Hemophilia Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Hemophilia Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Hemophilia Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
